CBL combined with gefitinib could suppress A549 cell viability and promote cell apoptosis by downregulating hepatocyte growth factor (HGF) protein expression and blocking cell-mesenchymal epidermal transformation factor (c-Met) gene amplification, which indicated that CBL might delay the occurrence of gefitinib resistance in lung cancer cells. This evidence concerns the gene HGF and lung cancer.